LORVEN BIOLOGICS PRIVATE LIMITED
Company Overview )
Total Bids
1
Contract Value
₹1.42 Cr
L1 Bids
1
Recent Win Rate
0.0%
Executive Summary
Lorven Biologics Private Limited is making its presence felt in the Indian government tender ecosystem, particularly within the Ministry of Defence. With participation in 1 tender between April 2022 and March 2023, Lorven Biologics has achieved a remarkable 100.0% win rate, securing 1 L1 position. Their technical qualification rate also stands at an impressive 100.0% for the same period, showcasing their capability to meet stringent government requirements.
Their financial health is assessed as 'Good' with a score of 77.5/100, driven by strong performance in win rate (100/100) and contract value (100/100). However, there is room for improvement in consistency (0/100).
Lorven Biologics's strategic focus within the Department of Defence Research & Development indicates a specialized approach to government procurement. This focused approach could be a key differentiator in a competitive market.
Financial Performance Analysis
Yearly Trends
Lorven Biologics began participating in government tenders in FY2022-23, securing a single contract. There were no bids in FY 2018-19, FY 2019-20, FY 2020-21, FY 2021-22, FY 2023-24 and FY 2024-25.
| Fiscal Year | Bid Count | Win Count | Qualification Rate | Win Rate | Total Contract Value |
|---|---|---|---|---|---|
| FY 2018-19 | 0 | 0 | 0.0% | 0.0% | ₹0 |
| FY 2019-20 | 0 | 0 | 0.0% | 0.0% | ₹0 |
| FY 2020-21 | 0 | 0 | 0.0% | 0.0% | ₹0 |
| FY 2021-22 | 0 | 0 | 0.0% | 0.0% | ₹0 |
| FY 2022-23 | 1 | 1 | 100.0% | 100.0% | ₹1,41,60,000 |
| FY 2023-24 | 0 | 0 | 0.0% | 0.0% | ₹0 |
| FY 2024-25 | 0 | 0 | 0.0% | 0.0% | ₹0 |
From April 2023 to March 2024, Lorven Biologics focused its bidding efforts on tenders within the ₹1.4 crore price range, securing one bid at that level.
Product/Service Category Performance
Data is insufficient to provide a detailed breakdown of performance by product or service category.
Geographical & Departmental Distribution
Lorven Biologics's primary focus is on the Department of Defence Research & Development under the Ministry of Defence. Data is currently insufficient to provide a state-wise analysis.
Competitive Analysis
Head-to-Head Comparisons
From Jan 2022 to Dec 2023, Lorven Biologics faced direct competition from LINK BIOTECH and TAMILNADU GREEN POWER TECH. While Lorven Biologics has a 100.0% win rate in the tenders it participated, it did not win against these specific competitors during the defined period.
| Competitor Name | Encounter Count | Wins Against Lorven Biologics | Win Rate Against Lorven Biologics |
|---|---|---|---|
| LINK BIOTECH | 1 | 0 | 0.0% |
| TAMILNADU GREEN POWER TECH | 1 | 0 | 0.0% |
Within the Ministry of Defence, Lorven Biologics is encountering competition from LINK BIOTECH and TAMILNADU GREEN POWER TECH. They have not secured any wins against these competitors.
Threat Assessment
The presence of direct competitors like LINK BIOTECH and TAMILNADU GREEN POWER TECH poses a potential threat. Lorven Biologics needs to develop strategies to outperform these competitors in future tenders.
SWOT Analysis of Lorven Biologics Private Limited
Strengths
- High Qualification Rate: 100.0% technical qualification rate demonstrates strong compliance.
- Focused Departmental Expertise: Specialization in tenders from the Department of Defence Research & Development.
- Strong Financial Health Score: High score indicates good financial performance.
Weaknesses
- Limited Tender Participation: Participation in only one tender limits the scope of analysis.
- Lack of Wins Against Direct Competitors: No wins against LINK BIOTECH or TAMILNADU GREEN POWER TECH.
Opportunities
- Expand Tender Portfolio: Increase the number of tenders participated in to gather more data.
- Develop Competitive Strategies: Create strategies to outperform competitors in Ministry of Defence tenders.
- Explore New Departments: Diversify tender participation across different government departments.
Threats
- Intense Competition: Presence of established players like LINK BIOTECH and TAMILNADU GREEN POWER TECH.
- Limited Data: Insufficient data for comprehensive performance analysis.
Strategic Recommendations
- Increase Tender Participation: Actively seek and participate in more tenders to expand the portfolio and gather more data.
- Develop Competitive Strategies: Analyze competitor strengths and weaknesses to develop strategies for outperforming them.
- Diversify Departmental Focus: Explore tender opportunities in other government departments to reduce dependence on a single entity.
Future Growth Outlook
Based on initial trends, Lorven Biologics has the potential for growth in the government tender market. Their strong qualification rate and focus on the Defence sector provide a solid foundation. However, they need to increase their tender participation and develop strategies to compete effectively with established players. Continuous monitoring of sector dynamics and proactive adaptation to changing procurement landscapes will be crucial for sustained success.